Neuren Pharmaceuticals Management
Management criteria checks 4/4
Neuren Pharmaceuticals' CEO is Jon Pilcher, appointed in May 2020, has a tenure of 5.08 years. total yearly compensation is A$668.40K, comprised of 93% salary and 7% bonuses, including company stock and options. directly owns 0.32% of the company’s shares, worth A$4.99M. The average tenure of the management team and the board of directors is 2.9 years and 6.9 years respectively.
Key information
Jon Pilcher
Chief executive officer
AU$668.4k
Total compensation
| CEO salary percentage | 92.96% |
| CEO tenure | 5.1yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.9yrs |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
Neuren Pharmaceuticals Limited (ASX:NEU) Shares Fly 30% But Investors Aren't Buying For Growth
May 16
DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks
Strong financial position and partnerships reduce the need for capital raising, protecting margins and earnings.Investors Don't See Light At End Of Neuren Pharmaceuticals Limited's (ASX:NEU) Tunnel
Apr 01A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 06Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching
Jan 15New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)
Nov 11Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up
Nov 08Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Oct 24Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Aug 29Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Aug 14Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
May 31Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
May 03An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Apr 01Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Mar 05Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
Mar 02Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Dec 18Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Sep 02Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Aug 31This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Mar 03Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | AU$668k | AU$621k | AU$142m |
| Sep 30 2024 | n/a | n/a | AU$130m |
| Jun 30 2024 | n/a | n/a | AU$117m |
| Mar 31 2024 | n/a | n/a | AU$137m |
| Dec 31 2023 | AU$1m | AU$549k | AU$157m |
| Sep 30 2023 | n/a | n/a | AU$106m |
| Jun 30 2023 | n/a | n/a | AU$55m |
| Mar 31 2023 | n/a | n/a | AU$28m |
| Dec 31 2022 | AU$546k | AU$396k | AU$184k |
| Sep 30 2022 | n/a | n/a | -AU$3m |
| Jun 30 2022 | n/a | n/a | -AU$7m |
| Mar 31 2022 | n/a | n/a | -AU$7m |
| Dec 31 2021 | AU$432k | AU$203k | -AU$8m |
Compensation vs Market: Jon's total compensation ($USD433.72K) is below average for companies of similar size in the Australian market ($USD1.08M).
Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.
CEO
Jon Pilcher
Mr. Jonathan Charles Pilcher, also known as Jon, BSc (Hons), ACA, FCA serves as Managing Director & Executive Director at Neuren Pharmaceuticals Limited since June 14, 2021. He had been a Company Secretary...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Executive Director | 5.1yrs | AU$668.40k | 0.32% A$ 5.0m | |
| CFO & Company Secretary | 4.8yrs | no data | no data | |
| Chief Operations Officer | 1.4yrs | no data | no data | |
| Chief Science Officer | 21.4yrs | no data | no data | |
| Chief Business Officer | 1.4yrs | no data | no data | |
| Chief Medical Officer | 2.9yrs | no data | no data | |
| Chief Regulatory Officer | less than a year | no data | no data |
Experienced Management: NEU's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Executive Director | 4yrs | AU$668.40k | 0.32% A$ 5.0m | |
| Independent Non-Executive Director | 6.9yrs | AU$87.50k | 0.024% A$ 376.3k | |
| Independent Non-Executive Director | 6.9yrs | AU$90.00k | 0.024% A$ 371.9k | |
| Independent Non-Executive Chairman | 6.9yrs | AU$157.50k | 0.21% A$ 3.3m | |
| Independent Non-Executive Director | 2.3yrs | AU$90.00k | 0.029% A$ 450.3k |
Experienced Board: NEU's board of directors are considered experienced (6.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/20 21:04 |
| End of Day Share Price | 2025/06/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuren Pharmaceuticals Limited is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| Melissa Benson | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |